Ionis Pharmaceuticals (MEX:IONS) Shiller PE Ratio: (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
64 GF Score
Price MXN960.00
GF Value MXN683.49
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ionis Pharmaceuticals  (MEX:IONS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ionis Pharmaceuticals Shiller PE Ratio Related Terms


Ionis Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Shiller PE Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:IONS vs APGE, CYTK, KRYS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shiller PE Ratio falls into.


MEX:IONS
64GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ionis Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-12.04/333.9520*333.9520
=-12.040

Current CPI (Jun. 2026) = 333.9520.

Ionis Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 1.160 241.428 1.605
201612 4.330 241.432 5.989
201703 1.318 243.801 1.805
201706 -0.362 244.955 -0.494
201709 -0.363 246.819 -0.491
201712 0.393 246.524 0.532
201803 -0.182 249.554 -0.244
201806 -5.698 251.989 -7.551
201809 -0.561 252.439 -0.742
201812 43.393 251.233 57.680
201903 12.027 254.202 15.800
201906 -0.192 256.143 -0.250
201909 3.554 256.759 4.622
201912 24.141 256.974 31.373
202003 -6.565 258.115 -8.494
202006 -4.155 257.797 -5.382
202009 -3.976 260.280 -5.101
202012 -48.536 260.474 -62.228
202103 -13.082 264.877 -16.494
202106 -11.346 271.696 -13.946
202109 -11.926 274.310 -14.519
202112 28.925 278.802 34.647
202203 -9.159 287.504 -10.639
202206 -14.887 296.311 -16.778
202209 -6.638 296.808 -7.469
202212 -7.214 296.797 -8.117
202303 -15.682 301.836 -17.351
202306 -10.286 305.109 -11.258
202309 -17.941 307.789 -19.466
202312 -1.018 306.746 -1.108
202403 -16.264 312.332 -17.390
202406 -8.244 314.175 -8.763
202409 -18.706 315.301 -19.813
202412 -13.765 315.605 -14.565
202503 -19.026 319.799 -19.868
202506 13.180 322.561 13.645
202509 -14.675 324.800 -15.089
202512 -25.388 324.054 -26.163
202603 -10.098 330.213 -10.212
202606 -12.040 333.952 -12.040

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN960.00 is trading 40.5% above its estimated GF Value™ of MXN683.49. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:IONS:

  • Shiller PE Ratio:
  • GF Value™: MXN683.49 vs. price of MXN960.00 (40.5% above fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
64GF Score

Get the complete analysis for MEX:IONS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN960.00
Price
MXN683.49
GF Value